RHY 8.57% 7.6¢ rhythm biosciences limited

Why wouldn't it be intended as a replacement for current testing...

  1. 562 Posts.
    lightbulb Created with Sketch. 86
    Why wouldn't it be intended as a replacement for current testing methodology?

    "GlycoKnow Colon is intended to be complementary to—and not a replacement for—current recommended colorectal cancer testing"
 
watchlist Created with Sketch. Add RHY (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.